[Pneumocystis pneumonia in patients with immunosuppression other than HIV infection].
Pneumocystis jirovecii is an opportunistic pathogen causing life-threatening pneumonia in immunosuppressed patients. The number of non-HIV immunosuppressed patients at risk for Pneumocystis pneumonia is rapidly growing. In contrast to HIV patients, there are no guidelines for Pneumocystis prophylaxis in other immunocompromised hosts. A detailed analysis of current literature data allowed us hereby to define the type of immunocompromised patients for whom evidence suggests a benefit for PCP prophylaxis.
Adler
Dan
D
Service de pneumologie et reanimation Groupe, hospitalier Pitié-Salpêtrière 75651 Paris cedex 13, France. dan.adler@hcuge.ch
Chenivesse
Cécile
C
Similowski
Thomas
T
Soccal
Paola Marina
PM
D000890:Anti-Infective Agents / Q000008:administration & dosage*; D003240:Connective Tissue Diseases / Q000150:complications; D064420:Drug-Related Side Effects and Adverse Reactions; D019317:Evidence-Based Medicine; D015658:HIV Infections; D006801:Humans; D016867:Immunocompromised Host; D009369:Neoplasms / Q000150:complications; D045363:Pneumocystis carinii; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011502:Protein-Energy Malnutrition / Q000150:complications; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D014180:Transplantation / Q000009:adverse effects; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage*; D014657:Vasculitis / Q000150:complications
D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination